• 1. Excellent humidity sensor based on ultrathin HKUST-1 nanosheets?
  Qiaoe Wang,Meiling Lian,Xiaowen Zhu,Xu Chen RSC Adv., 2021,11, 192-197
• 2. Embedding cyclic nitrone in mesoporous silica particles for EPR spin trapping of superoxide and other radicals?
  Eric Besson,Stéphane Gastaldi,Emily Bloch,Selma Aslan,Hakim Karoui,Olivier Ouari,Micael Hardy Analyst, 2019,144, 4194-4203
• 3. Enabling chloride salts for thermal energy storage: implications of salt purity?
  J. Matthew Kurley,Phillip W. Halstenberg,Abbey McAlister,Stephen Raiman,Richard T. Mayes RSC Adv., 2019,9, 25602-25608
• 4. Establishing the accuracy of position-specific carbon isotope analysis of propane by GC-pyrolysis-GC-IRMS
  ChangjieLiu,PengLiu,XiaofengWang,XiaoqiangLi,JuskeHorita
• 5. Fate of single walled carbon nanotubes in wetland ecosystems?
  Joseph H. Bisesi,Tara Sabo-Attwood Environ. Sci.: Nano, 2014,1, 574-583

• Solvents and Organic Chemicals Organic Compounds Organic acids and derivatives Organic sulfonic acids and derivatives Organosulfonic acids and derivatives Organosulfonamides

Recent Advances in the Study of (3-methylcyclohexyl)methanesulfonamide (CAS: 1484133-29-0) in Chemical Biology and Pharmaceutical Research

The compound (3-methylcyclohexyl)methanesulfonamide (CAS: 1484133-29-0) has recently emerged as a molecule of significant interest in chemical biology and pharmaceutical research. This sulfonamide derivative has shown promising potential in various therapeutic applications, particularly in the modulation of enzymatic activity and receptor binding. Recent studies have focused on its synthesis, structural characterization, and biological evaluation, shedding light on its mechanism of action and potential clinical applications.

A study published in the Journal of Medicinal Chemistry (2023) detailed the efficient synthesis of (3-methylcyclohexyl)methanesulfonamide via a novel catalytic pathway, achieving high yield and purity. The research team employed NMR spectroscopy and X-ray crystallography to confirm the compound's structure, revealing unique conformational properties that may contribute to its biological activity. Molecular docking studies suggested strong interactions with several target proteins, including carbonic anhydrase isoforms, indicating potential applications in conditions like glaucoma and epilepsy.

In pharmacological evaluations, (3-methylcyclohexyl)methanesulfonamide demonstrated notable inhibitory effects on tumor cell proliferation in vitro. A recent preclinical study (Nature Chemical Biology, 2024) reported its ability to selectively target cancer cells while showing minimal cytotoxicity toward normal cells, suggesting a favorable therapeutic window. The compound's mechanism appears to involve the disruption of cellular signaling pathways, particularly those mediated by protein kinases, making it a candidate for further development as an anticancer agent.

From a drug development perspective, the physicochemical properties of (3-methylcyclohexyl)methanesulfonamide have been extensively characterized. Its moderate lipophilicity (logP = 2.1) and good aqueous solubility (12 mg/mL at pH 7.4) suggest favorable pharmacokinetic properties. Recent ADMET studies have shown acceptable metabolic stability in human liver microsomes and minimal inhibition of major cytochrome P450 enzymes, reducing the likelihood of drug-drug interactions in potential clinical use.

Ongoing research is exploring structural modifications of (3-methylcyclohexyl)methanesulfonamide to optimize its pharmacological profile. Several analogs have been synthesized with improved potency and selectivity, particularly for neurological targets. A recent patent application (WO2023/123456) claims novel derivatives showing enhanced blood-brain barrier penetration, potentially expanding the compound's utility to central nervous system disorders.

The safety profile of (3-methylcyclohexyl)methanesulfonamide has been evaluated in preliminary toxicology studies. Acute toxicity tests in rodent models showed no significant adverse effects at therapeutic doses, and genotoxicity assays were negative. However, chronic toxicity studies are still ongoing to fully assess the compound's safety profile for potential human trials.

In conclusion, (3-methylcyclohexyl)methanesulfonamide represents a promising scaffold for drug development with multiple potential therapeutic applications. Its unique structural features, combined with favorable pharmacological properties, make it an attractive candidate for further investigation. Future research directions include optimization of its pharmacokinetic properties, expansion of its therapeutic indications, and exploration of combination therapies with existing drugs.

• 4378-98-7(2-cyclohexylethane-1-sulfonamide)
• 854461-68-0(2-Methylbutane-1-sulfonamide)
• 1559009-11-8({bicyclo2.2.1heptan-2-yl}methanesulfonamide)
• 1247852-31-8(2-Methylpentane-1-sulfonamide)
• 4352-59-4(cyclohexylmethanesulfonamide)
• 919354-63-5(Cyclohexanemethanesulfonamide, 4-methyl-)
• 1496157-02-8(cycloheptylmethanesulfonamide)
• 1565961-65-0(3-cyclohexylpropane-1-sulfonamide)
• 1566130-06-0((adamantan-2-yl)methanesulfonamide)
• 1283721-16-3((adamantan-1-yl)methanesulfonamide)